Guía OncoSur de Cáncer de mama 78 > PUNTOS CLAVES En resumen, el tratamiento neoadyuvante del cáncer de mama triple negativo se basa en la combinación de antraciclinas y taxanos de manera secuencial. Añadir platinos puede considerarse una opción en pacientes con este tipo de tumores. En un futuro se verá si la inmunoterapia constituirá parte del tratamiento estándar para estos pacientes. BIBLIOGRAFÍA 1. Cortázar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;12;384(9938):164-72. 2. Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016;17:345-56. 3. Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: ARandomized Phase 3 Clinical Trial. JAMA Oncology. 2018;4(3):302-8. 4. Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497-508. 5. Von Minckwitz G, Loibl S, Schneeweiss A, Salat CT, Rezai M, Zahm DM, et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 8-12, 2015; Abstract S2-04. 6. Sikov WM, Berry DA, Perou CM, Singh B, Cirrinciones CT, Tolaney SM, et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 8-12, 2015; Abstract S2-05. 7. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017;376:2147-59. 8. Natori A, Ethier JL, Amir E, Cescon DW. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. Eur J Cancer. 2017;77:40-7. 9. Neoadjuvant Pembrolizumab Takes on TNBC. Cancer Discov. 2019 Oct;9(10):OF4.
RkJQdWJsaXNoZXIy MTQzMjMwMg==